FFO
AVTX icon

Fortitude Family Office’s Avalo Therapeutics AVTX Stock Holding History

Fortitude Family Office’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$554 Sell
30
-33
-52% -$522 ﹤0.01% 1953
2026
Q1 		$941 Buy
+63
New +$985 ﹤0.01% 1523

Other funds holding AVTX

NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PP
PFS Partners Mine Hill, New Jersey $247M AUM 29.02% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
KFI
Key Financial Inc West Chester, Pennsylvania $611M AUM 21.11% 1-Year Est. Return

Fortitude Family Office's AVTX Position: Q2 2026 in Review

Fortitude Family Office reduced its Avalo Therapeutics (AVTX) stake by 52% in Q2 2026, selling an estimated $522 and leaving 30 shares worth $554. The position accounts for ﹤0.01% of the portfolio, ranked #1953.

Fortitude Family Office first reported a position in AVTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $941 in Q1 2026. 8 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Fortitude Family Office held 30 shares of Avalo Therapeutics worth $554 as of Q2 2026.
  • Fortitude Family Office sold 33 Avalo Therapeutics shares in Q2 2026, an estimated $522.
  • Avalo Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #1953 holding.
  • Fortitude Family Office first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Fortitude Family Office's Avalo Therapeutics position peaked at $941 in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.